MedTrace Logo

Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment

NCT00645164 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2010-06-08

Study results available
· View outcomes & findings →

Summary

The product is being tested to see if exposure to light causes photoallergic reactions on the skin.

Conditions

  • Healthy

Interventions

OTHER

Ointment Vehicle

Subject acts as own control. 20 mg under Finn chambers

DRUG

Xenaderm

20 mg under Finn chambers

Sponsors & Collaborators

  • Healthpoint

    lead INDUSTRY

Principal Investigators

  • Joe Stanfield, PhD · Suncare Research Laboratories

Study Design

Allocation
NA
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-05-31
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00645164 on ClinicalTrials.gov